Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of almost 20 different brokers. See the list of analysts and their contact details here

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.  

 ucb

UCB FY Consensus Product Sales Estimates (Average)

In € million 2017a 2018e 2019e 2020e  2021e  2022e  2023e
Cimzia 1,424 1,457 1,503 1,510 1,503 1,463 1,443
Vimpat 976 1,084 1,201 1,310 1,417 1,127 771
Neupro 314 321 338 352 313 260 218
Briviact 87 148 220 288 351 409 466
Keppra 778 750 714 675 615 569 521

 

UCB FY Consensus Earnings Estimates (Average)

In € million 2017a 2018e 2019e 2020e 
Net Sales  4,182 4,313  4,496  4,657 
Revenue  4,530 4,579 4,747 4,900
Recurring EBIT 1,130  1,113 1,152 1,229
Recurring EBITDA 1,375  1,356 1,393 1,472
Net Profit   753 811 837 907
Core EPS (€) 4.82  4.67 4.83 5.20

 

UCB FY Consensus Product Sales Estimates (Median)

In € million 2017a 2018e 2019e 2020e  2021e  2022e  2023e
Cimzia 1,424 1,461 1,495 1,518 1,492 1,438 1,396
Vimpat 976 1,085 1,195 1,280 1,369 1,125 726
Neupro 314 319 334 351 311 246 210
Briviact 87 148 219 288 351 410 466
Keppra 778 753 707 671 617 576 534

 

UCB FY Consensus Earnings Estimates (Median)

In € million 2017a 2018e 2019e 2020e 
Net Sales  4,182 4,307 4,507  4,665 
Revenue  4,530 4,569 4,740 4,882
Recurring EBIT 1,130  1,119 1,142 1,227
Recurring EBITDA  1,375 1,347 1,391 1,474
Net Profit  753  792 812 887
Core EPS (€)  4.82 4.68 4.86 5.22

Downloads:
UCB FY 2018 Consensus (Excel)
UCB FY P&L Consensus (PDF)
UCB FY Product Sales Consensus (PDF)

Last updated: 13 November, 2018



Check out UCB's new IR Apps: 

App Apple Store

App Google Play

 

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.